According to an American College of Obstetricians and Gynecologists (ACOG) practice bulletin, two prostaglandin E2 (PGE2) preparations are commercially available: a gel in a 2.5 mL syringe containing 0.5 mg of dinoprostone (Prepidil®) and a vaginal insert containing 10 mg of dinoprostone (Cervidil®), of which both are FDA approved for cervical ripening in women at or near term. Compared with placebo or oxytocin alone, vaginal prostaglandins used for cervical ripening have been observed to increase the likelihood of delivery within 24 hours, but with an increase of uterine tachysystole with associated fetal heart rate (FHR) changes and without a reduction in the rate of cesarean delivery. Misoprostol administered intravaginally has been reported to be either superior to or as efficacious as dinoprostone gel. Additionally, misoprostol has been found to cause less use of epidural analgesia, more vaginal deliveries within 24 hours, and more uterine tachysystole with or without FHR changes compared with dinoprostone and oxytocin. [1]
It is stated that the benefits of using oral misoprostol for labor induction are that it is low in cost, noninvasive, stable at room temperature, and is associated with lower cesarean rates than other induction methods. Additionally, it may lead to less uterine hyperstimulation with FHR changes as compared to vaginal misoprostol. However, despite its’ benefits, it notes that the optimal dose for safety is yet to to be determined. Compared to the oral route, benefits of vaginal misoprostol are similar with additional benefit of achieving a higher plasma level. It also is stated to be more efficacious at cervical ripening and induction of labor compared to oxytocin and dinoprostone. However, it is noted that vaginal misoprostol is associated with more uterine hyperstimulation and meconium-stained fluid when compared to other vaginal induction methods. Furthermore, slow or erratic absorption can occur with vaginal misoprostol, which may result in inaccurate dosing. A stated advantage of using dinoprostone vaginal insert is that it is able to be removed quickly in the case of FHR changes, which may resolve within 15 minutes after removing the insert. It is noted, however, that vaginal dinoprostone is associated with a 5% chance of uterine hyperstimulation one hour after administration. [2]
A 2024 systematic review and meta-analysis examined the efficacy and safety of intravaginal misoprostol compared to dinoprostone for labor induction at term. This analysis involved eight randomized controlled trials (RCTs) with a total of 1,801 participants, including 937 women in the misoprostol group and 864 in the dinoprostone group. The study population consisted of singleton pregnant women with live intrauterine gestations and unfavorable cervices, ranging from 37 to 42 weeks of gestation. The primary objective was to analyze key maternal and neonatal outcomes, such as the rates of vaginal delivery within 24 hours, cesarean delivery, and the necessity for oxytocin augmentation. Misoprostol was associated with a significantly reduced need for oxytocin augmentation compared to dinoprostone (risk ratio [RR] 0.83; 95% confidence interval [CI] 0.71 to 0.97; p= 0.02). However, other outcomes, including cesarean delivery rates, uterine tachysystole, hyperstimulation, NICU admissions, and APGAR scores, showed no significant differences between the two groups, suggesting similar safety and efficacy profiles. Notably, the analysis revealed no significant heterogeneity among studies regarding vaginal delivery within 24 hours, cesarean delivery, and instrumental delivery. Despite varying dosages and administration regimens across trials, the authors suggest that intravaginal misoprostol is an effective and safe alternative to dinoprostone for labor induction in clinical settings, offering the advantage of requiring less oxytocin augmentation. [3]
Another 2024 systematic review and updated meta-analysis involving 53 RCTs (N= 10,455 patients) assessed the efficacy and safety of oral and vaginal misoprostol compared to dinoprostone for labor induction in women. Vaginal misoprostol showed a statistically significant higher success rate for labor induction compared to vaginal dinoprostone (RR 1.14; 95% CI 1.08 to 1.21; p<0.00001; I2= 69%), with less need for additional oxytocin (RR 0.67; 95% CI 0.59 to 0.76; p<0.00001; I2= 82%). However, vaginal misoprostol was associated with a higher incidence of uterine hyperstimulation, tachysystole, and abnormal cardiotocography compared to dinoprostone. There were no significant differences in cesarean section rates or neonatal intensive care unit admissions between the groups. Interestingly, oral misoprostol was found to have comparable safety profiles to vaginal dinoprostone, providing similar efficacy without increased risks of adverse outcomes, making it a potential alternative for labor induction. These findings suggest that while vaginal misoprostol is effective, its safety profile must be carefully considered, and oral misoprostol may offer a safer, equally effective option. [4]
A 2024 individual participant data meta-analysis of randomized controlled trials examined the effectiveness and safety of induction of labor using low-dose vaginal misoprostol compared to vaginal dinoprostone. This analysis combined data from eight trials, encompassing 4,180 women (low-dose vaginal misoprostol, n= 2,077; vaginal dinoprostone, n= 2,103) to evaluate the primary outcomes, which included vaginal delivery rates, composite adverse perinatal outcomes, and composite adverse maternal outcomes. Low-dose vaginal misoprostol and vaginal dinoprostone were observed to have comparable rates of vaginal birth and similar perinatal safety profiles. Notably, use of low-dose vaginal misoprostol was associated with a significantly lower rate of composite adverse maternal outcomes compared to vaginal dinoprostone (adjusted odds ratio [OR] 0.80; 95% CI 0.65 to 0.98; p= 0.03; I2= 0%). Despite the comparable effectiveness in achieving vaginal delivery, the distinct advantage of low-dose vaginal misoprostol lies in its better maternal safety profile, characterized by a trend toward lower maternal infection rates and reduced intensive care unit admissions among participants. Overall, low-dose vaginal misoprostol may not only be a viable alternative to vaginal dinoprostone for cervical ripening and labor induction, but also offer benefits in terms of maternal safety, particularly in resource-limited settings where cost-effectiveness is crucial. [5]
Finally, a 2023 systematic review and meta-analysis synthesized data from 39 RCTs involving 15,993 participants to evaluate the safety profiles of misoprostol and dinoprostone for labor induction in women with singleton pregnancies beyond 36 weeks' gestation. Maternal outcomes analyzed included cesarean section rate, instrumental deliveries, tachysystole, uterine rupture, postpartum hemorrhage, and chorioamnionitis. Neonatal outcomes encompassed five-minute Apgar scores of less than 7, meconium-stained amniotic fluid, NICU admissions, and infant mortality. No statistically significant differences were identified between misoprostol and dinoprostone in the primary outcomes of cesarean delivery (OR 0.94; 95% CI 0.84 to 1.05) or instrumental delivery (OR 1.04; 95% CI 0.90 to 1.19). Rates of uterine tachysystole were comparable between groups overall (OR 1.21; 95% CI 0.91 to 1.60), though a subgroup analysis revealed heightened tachysystole with vaginal misoprostol compared to dinoprostone gel (OR 1.48; 95% CI 1.09 to 2.01). There was no significant difference in postpartum hemorrhage (OR 0.85; 95% CI 0.62 to 1.15), neonatal Apgar scores <7 (OR 0.83; 95% CI 0.61 to 1.12), or NICU admissions (OR 0.91; 95% CI 0.77 to 1.09). The findings suggest a comparable safety profile between the two agents, with no clear superiority for either in any maternal or neonatal outcomes. [6]